{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:25:07Z","timestamp":1794540307697,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05124-1","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T18:13:51Z","timestamp":1649700831000},"page":"1947-1954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-4624","authenticated-orcid":false,"given":"Ichiro","family":"Yoshii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsumi","family":"Chijiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"5124_CR1","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL (2018) Biologic refractory disease in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 77:1405\u20131412. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213378","journal-title":"Ann Rheum Dis"},{"key":"5124_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/rheumatology\/kex349","volume":"57","author":"MJH de Hair","year":"2018","unstructured":"de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM (2018) Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford) 57:1135\u20131144. https:\/\/doi.org\/10.1093\/rheumatology\/kex349","journal-title":"Rheumatology (Oxford)"},{"key":"5124_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M B\u00e9c\u00e8de","year":"2019","unstructured":"B\u00e9c\u00e8de M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D (2019) Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum 49:211\u2013217. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.004","journal-title":"Semin Arthritis Rheum"},{"key":"5124_CR4","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2017-212862","volume":"77","author":"MH Buch","year":"2018","unstructured":"Buch MH (2018) Defining refractory rheumatoid arthritis. Ann Rheum Dis 77:1705\u20131709. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212862","journal-title":"Ann Rheum Dis"},{"key":"5124_CR5","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","volume":"60","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber F, Jacobs JWG, van Laar JM (2021) Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford) 60:3778\u20133788. https:\/\/doi.org\/10.1093\/rheumatology\/keaa860","journal-title":"Rheumatology (Oxford)"},{"issue":"Supplement 1","key":"5124_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/annrheumdis-2021-eular.1221","volume":"80","author":"Y Hirano","year":"2021","unstructured":"Hirano Y, Hasegawa J, Kosugiyama H, Kihira D, Hattori K (2021) Incidence rates of difficult-to-treat rheumatoid arthritis in real-world clinical practice. Ann Rheum Dis 80(Supplement 1):455. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.1221","journal-title":"Ann Rheum Dis"},{"key":"5124_CR7","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","volume":"60","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T (2021) Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology 60:5247\u20135256. https:\/\/doi.org\/10.1093\/rheumatology\/keab209","journal-title":"Rheumatology"},{"key":"5124_CR8","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"5124_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis"},{"key":"5124_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/acr22456","volume":"67","author":"BR England","year":"2015","unstructured":"England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K (2015) Validation of the rheumatic disease comorbidity index. Arthritis Care Res 67:865\u2013872. https:\/\/doi.org\/10.1002\/acr22456","journal-title":"Arthritis Care Res"},{"key":"5124_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/CEOR.S89833","volume":"7","author":"A Igarashi","year":"2015","unstructured":"Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M (2015) Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan. Clinicoecon Outcomes Res 7:505\u2013520. https:\/\/doi.org\/10.2147\/CEOR.S89833","journal-title":"Clinicoecon Outcomes Res"},{"key":"5124_CR12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","volume":"77","author":"NMT Roodenrijs","year":"2018","unstructured":"Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D et al (2018) Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 77:1705\u20131709. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213687","journal-title":"Ann Rheum Dis"},{"key":"5124_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-00512","volume":"7","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, Welsing PMJ (2021) Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 7:e001512. https:\/\/doi.org\/10.1136\/rmdopen-2020-00512","journal-title":"RMD Open"},{"key":"5124_CR14","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/annrheumdis-2021-220315","volume":"80","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T (2021) Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:1491\u20131493. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220315","journal-title":"Ann Rheum Dis"},{"key":"5124_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y (2022) Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther 24:61. https:\/\/doi.org\/10.1186\/s13075-022-02744-7","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T15:11:08Z","timestamp":1664205068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["5124"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05124-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ichiro Yoshii, Naoya Sawada, and Tatsumi Chijiwa declare that they have no conflict of interest. And their families have nothing to declare for this study. None of author and his families have share income, property with any person, or any grants or other financial supports of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by our ethics committee (approval number: YH-RA-2021-3) in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. In addition, anonymity was ensured for all patients and families who participated in this study, and no names and\/or addresses were issued that could help identify these individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}